Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics:

• Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00)
• Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38)
• Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32)
• Tolerability profile of lorlatinib (23:28)
• Review of clinical investigator survey results (37:08)
• Novel ALK inhibitors under clinical development (53:31)

CME information and select publications

Featuring an interview with Dr Adrienne G Waks, including the following topics:

• The Phase III AFT-38 PATINA trial of palbociclib combined with anti-HER2 therapy for hormone receptor (HR)-positive/HER2-positive metastatic breast cancer (mBC) (0:00)
• Role of immunotherapy in the treatment of breast cancer (8:30)
• Defining ER-low breast cancer and identifying treatment approaches for this histologic subtype (15:55)
• Genomic testing approaches for patients with localized breast cancer and identification of candidates for treatment with adjuvant olaparib (19:37)
• Current role of anthracyclines in the treatment of localized breast cancer (31:17)
• Available and novel antibody-drug conjugates for the treatment of breast cancer (41:21)
• Palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for HR-positive, HER2-negative mBC (51:53)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Adrienne G Waks, including the following topics:

• Updated analyses from key studies of the 21-gene Recurrence Score® for localized ER-positive breast cancer (29:30)
• Four-year landmark analysis of the NATALEE trial of adjuvant ribociclib with nonsteroidal aromatase inhibitor for localized breast cancer (9:49)
• The PADMA trial of palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (mBC) (11:25)
• Imlunestrant with or without abemaciclib for metastatic ER-positive mBC (13:18)
• TROP2-directed antibody-drug conjugates (ADCs) datopotamab deruxtecan and sacituzumab tirumotecan for HR-positive/HER2-negative mBC (17:50)
• Recent analyses from the DESTINY-Breast06 trial of trastuzumab deruxtecan (T-DXd) after endocrine therapy for HR-positive, HER2-low or HER2-ultralow mBC (21:09)
• The ICARUS-BREAST01 Phase II trial of the HER3-targeted ADC patritumab deruxtecan for HR-positive/HER2-negative mBC (26:02)
• Updates from neoadjuvant/adjuvant trials of pembrolizumab (KEYNOTE-522) and atezolizumab (NSABP B-59/GBG 96-GeparDouze) for localized triple-negative breast cancer (TNBC) (27:36)
• Ten-year update of the OlympiA trial of adjuvant olaparib for patients with germline BRCA1/2-mutated HER2-negative localized breast cancer (31:23)
• Exploratory analysis of patients who did or did not receive prior PD-1/PD-L1 inhibition in the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan versus chemotherapy for previously treated advanced TNBC (32:56)
• CNS efficacy of T-DXd (DESTINY-Breast12 trial) and outcomes with palbociclib combined with anti-HER2 therapy (AFT-38 PATINA trial) for HER2-positive mBC (34:04)

CME information and select publications

Featuring an interview with Dr Catherine C Coombs, including the following topics:

• Case: A woman in her early 80s with dementia and newly diagnosed IGHV-mutated del(13q) chronic lymphocytic leukemia (CLL) receives initial treatment with zanubrutinib (0:00)
• Current and investigational initial therapy approaches for CLL (13:41)
• Case: A man in his late 40s under observation for asymptomatic CLL develops worsening symptoms and initiates treatment with venetoclax/obinutuzumab (28:15)
• Phase III AMPLIFY trial of fixed-duration acalabrutinib combined with venetoclax with or without obinutuzumab as first-line treatment for CLL (36:02)
• Other novel venetoclax combinations for the treatment of CLL (43:36)
• Case: A man in his mid 70s with multiregimen-refractory CLL receives pirtobrutinib (46:51)
• Personal perspectives on the activity and tolerability of pirtobrutinib; sequencing pirtobrutinib and chimeric antigen receptor T-cell therapy for patients with CLL (51:16)

CME information and select publications

Featuring perspectives from Dr Kathleen N Moore, Dr David M O’Malley and Dr Alessandro D Santin, moderated by Dr O’Malley, including the following topics:

• Introduction (0:00)
• Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Santin (2:17)
• Available Data with and Practical Application of HER2-Targeted Therapy for Advanced Gynecologic Cancers — Dr O'Malley (30:24)
• Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr Moore (1:01:53)

CME information and select publications

Featuring an interview with Dr Christopher L Moertel, including the following topics:

• Overview of neurofibromatosis type 1(NF1) (0:00)
• Cancer in NF1 (8:38)
• Dermatologic manifestations of NF1 (16:57)
• Treatment options for NF1 (20:43)
• Malignant peripheral nerve sheath tumors (MPNST) (25:14)
• FDA-approved MEK inhibitors for NF1 plexiform neurofibromas (28:36)
• Specializing in NF (44:44)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Christopher L Moertel, including the following topics:

• Overview of neurofibromatosis (0:00)
• Common clinical manifestations of neurofibromatosis type 1 (NF1) (14:13)
• Role of MEK inhibitors in the management of NF1 plexiform neurofibromas (29:30)

CME information and select publications

Featuring an interview with Dr Sara A Hurvitz, including the following topics:

• Role of endocrine therapy in the management of HER2-positive breast cancer; implications of the Phase III PATINA study (0:00)
• Case: A woman in her mid 60s with node-negative, HR-positive, HER2-negative localized breast cancer and a Recurrence Score® of 28 (8:38)
• Available data guiding the selection of an adjuvant CDK4/6 inhibitor (12:49)
• Selection of a CDK4/6 inhibitor in the metastatic setting (23:16)
• Available therapies for patients with HR-positive metastatic breast cancer (mBC) and PIK3CA mutations; implications of the Phase III INAVO120 study (29:17)
• Case: A woman in her early 60s with HR-positive, HER2-negative mBC with short duration of benefit from a first-line CDK4/6 inhibitor and an aromatase inhibitor (AI) and coexisting PIK3CA and ESR1 mutations (37:11)
• Available data with approved and investigational oral SERDs (selective estrogen receptor degraders) (43:23)
• Case: A woman in her early 70s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after durable responses to first-line endocrine therapy and second-line CDK4/6 inhibitor with an AI (51:38)
• Selection of therapy for patients with HR-positive mBC and coexisting targetable genetic mutations (53:11)
• Case: A woman in her late 50s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after first-line CDK4/6 inhibitor with an AI (1:00:17)

CME information and select publications

Featuring an interview with Dr Tiffany A Richards, including the following topics:

• Current treatment landscape for multiple myeloma (MM) (0:00)
• CAR (chimeric antigen receptor) T-cell therapy for the management of MM (10:22)
• Bispecific antibodies for relapsed/refractory MM (24:26)
• Case: A woman in her early 80s with relapsed MM receives teclistamab (35:56)
• Case: A man in his early 70s with multiregimen-refractory MM receives linvoseltamab on a clinical trial (44:06)
• Case: A woman in her early 60s with relapsed MM and extramedullary disease receives talquetamab (48:38)
• Role of nurses in transitions of care for patients with MM (53:15)
• Case: A man in his mid 70s with heavily pretreated MM experiences a response to teclistamab (58:56)
• Risk of second cancers with bispecific antibodies and other immunotherapy-based treatment approaches (1:00:55)

NCPD information and select publications

Featuring an interview with Dr Komal Jhaveri, including the following topics:

• Emerging treatment options for advanced ER-positive breast cancer (0:00)
  • Burstein H. Emerging treatment options for advanced ER+ breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01 Discussant.
• Elacestrant real-world progression-free survival for adult patients with ER-positive, HER2-negative advanced breast cancer: A retrospective analysis using insurance claims in the United States (7:28)
  • Swallow E et al. Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: A retrospective analysis using insurance claims in the United States. San Antonio Breast Cancer Symposium 2024;Abstract P3-10-08.
• Ongoing clinical trials involving oral SERDs (9:03)
  • Kaklamani V et al. ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-20.
  • An adjuvant endocrine-based therapy study of camizestrant (AZD9833) in ER+/HER2- early breast cancer (CAMBRIA-2). NCT05952557
  • Bardia A et al. ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-21.
• Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:48)
  • Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract

CME information and select publications